Engflag

Serta

Quick links to important sections

Serta

Serta_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Serta

What is Serta?

Serta is a medication containing the active ingredient sertraline. It belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs). These medications are primarily used to manage various mental health conditions by affecting the chemical balance in the brain.

Therapeutic Class and Mechanism

As an SSRI, Serta works by increasing the levels of serotonin, a neurotransmitter that facilitates communication between nerve cells. By preventing the reabsorption (reuptake) of serotonin into the neurons, the medication makes more of this chemical available in the synaptic gap, which can help improve mood, sleep, and appetite.

Primary Uses

Serta is commonly utilized in the treatment of several psychological and emotional conditions, including:

  • Major Depressive Disorder: Helping to alleviate persistent feelings of sadness and loss of interest.
  • Obsessive-Compulsive Disorder (OCD): Assisting in the management of repetitive thoughts and behaviors.
  • Panic Disorder: Reducing the frequency and intensity of unexpected panic attacks.
  • Social Anxiety Disorder: Addressing the intense fear of social situations or performance.
  • Post-Traumatic Stress Disorder (PTSD): Helping individuals process and manage symptoms following a traumatic event.
  • Premenstrual Dysphoric Disorder (PMDD): Managing severe physical and emotional symptoms that occur before the menstrual period.

Form and Administration

Serta is typically available in oral tablet form. The medication is designed for long-term use, and its effects are generally not immediate. It often takes several weeks of consistent use for the full therapeutic benefits to be observed. The specific application of Serta depends on the individual’s diagnosis and the clinical assessment of their symptoms.

Regulatory References

  1. Sertraline Information (NIH)

What side effects are possible with Serta?

Possible Side Effects and Safety Information

The safety profile of Serta (Sertraline) is documented through official regulatory classifications of adverse events, serious warnings, and constraints on use.

Adverse Reaction Scope

Classification Examples of Officially Documented Adverse Reactions
Very Common (ge 1/10) Nausea, Diarrhea, Insomnia, Ejaculation Failure (Male)
Common (ge 1/100 to < 1/10) Dizziness, Tremor, Somnolence, Dry Mouth, Fatigue, Decreased Libido, Hyperhidrosis (Increased Sweating)

The side effects are formally grouped into System-Organ Classes, primarily affecting the Gastrointestinal, Nervous System, and Psychiatric domains, with other effects noted in the cardiovascular and ocular systems.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (Label-Documented): Regulatory documents highlight risks for serious reactions, including Serotonin Syndrome, Activation of Mania/Hypomania, and increased risk of Bleeding. Rare, but significant, risks also include QTc Prolongation, Torsade de Pointes (TdP), and Angle-Closure Glaucoma. The risk of Suicidal Thoughts and Behaviors is noted as a specific concern in pediatric and young adult patients, particularly upon treatment initiation or dose change.

Population-Specific Safety: Caution is explicitly advised for patients with Hepatic Impairment due to reduced clearance. Older adults may be at a greater risk of developing Hyponatremia (low sodium levels).

Regulatory Constraints: The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) due to the high risk of Serotonin Syndrome. Caution is also advised for those with a history of Seizure or those with untreated anatomically narrow angles.

Connection to the Overall Safety Profile

The official safety information structures the understanding of the medicine's risks by separating the common, expected side effects from the serious, but less frequent, adverse reactions. This regulatory framework communicates the necessity for vigilance regarding serious warnings and highlights the importance of patient-specific factors, such as age and co-existing conditions, in determining the overall safety context.

Overdose and Emergency Response

Overdose and when to seek help

Category Official Regulatory Statements
Documented Manifestations Clinical signs reported include somnolence, agitation, tremor, and tachycardia. Gastrointestinal issues, such as nausea, vomiting, and diarrhea, are also documented presentations.
Severe Systemic Risk Reported outcomes involve delayed seizures, altered mental status including coma, and Serotonin Syndrome. Cardiovascular toxicity, including QTc interval prolongation and the potential for life-threatening arrhythmias, is a documented risk.
Exposure Factors Increased severity and the risk of death are reported when overdose involves Sertraline in combination with other drugs and/or alcohol.
Immediate Action Seek immediate medical attention for any suspected overdose. Contact emergency services or a Poison Control Center immediately, as overdosage must be medically treated aggressively.

Management Requirements

  • Antidote Status: No specific antidotes to Sertraline are known; therefore, care is reliant on general symptomatic and supportive measures.
  • Monitoring Mandate: Continuous ECG monitoring is recommended in all ingestions due to the potential for cardiac effects.
  • Procedural Note: Establishing and maintaining an airway is necessary. Gastrointestinal decontamination with activated charcoal should be considered in early presentations, though the induction of emesis is not recommended.

Therapeutic Uses of Serta

What Serta treats: main uses and benefits

Sertraline's therapeutic utility is commonly used across therapeutic domains where additional symptomatic support is needed, addressing symptoms that interfere with daily functioning and create noticeable functional strain. The medication is relevant when supportive symptom management is appropriate.

The medicine plays a role in managing core emotional and physiological manifestations across several key conditions, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder (PD), Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and Premenstrual Dysphoric Disorder (PMDD). The therapeutic focus is generally to contribute to easing the overall symptom burden and assist with maintaining functional stability when symptoms are more noticeable.

“The treatment is considered relevant across therapeutic areas involving symptoms related to systemic imbalance and heightened physiological activity.”

Quick Fact: Relief for Mood and Anxiety
Primary Goal Supports symptomatic management of severe emotional disturbances.
Key Scenarios Applied during phases when persistent symptoms interfere with routine activities.
Benefit Supports general well-being during symptomatic phases.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sertraline — official regulatory information

The following rules reflect the officially documented population eligibility and non-eligibility for Sertraline as defined by governmental regulatory documents.

Eligibility Scope

Category Eligibility Rule (Strictly Label-Based)
Populations for whom use is allowed Adults (18+), for all approved indications. Pediatric patients (6-17 years) for Obsessive-Compulsive Disorder (OCD) only.
Populations for whom use is contraindicated Patients with known Hypersensitivity to the drug; those using Monoamine Oxidase Inhibitors (MAOIs) or the antipsychotic Pimozide.
Populations for whom use is not recommended Children under 6 years (safety/efficacy not established); patients with Severe Hepatic Impairment; patients with Unstable Epilepsy.

Eligibility-Related Restrictions

Area of Restriction Official Regulatory Status
Hepatic Impairment Caution is required for mild impairment (may necessitate a reduced dose). Use is not recommended for moderate to severe impairment.
Pregnancy/Lactation Use in the late third trimester may increase the risk of neonatal adaptation symptoms. It is considered a preferred antidepressant during breastfeeding due to low levels in breast milk.
Comorbidity Use with caution in patients with a history of mania/hypomania or risk factors for QTc prolongation.

Connection to the overall eligibility profile

Official regulatory documents define absolute non-eligibility based on three key contraindications: hypersensitivity, concurrent MAOI use, and concurrent Pimozide use. Eligibility is also restricted by age, permitting pediatric use only for Obsessive-Compulsive Disorder in patients 6 years and older. Furthermore, official labeling advises avoidance or caution for patients with specific conditions, such as severe hepatic impairment or unstable epilepsy, due to altered drug clearance or increased risk profiles.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official government regulatory documents classify interactions with Serta based on clinical relevance and underlying mechanism.

Classification Interacting Agents (Examples) Constraint/Requirement
Contraindicated Combinations Monoamine Oxidase Inhibitors ( MAOIs), Pimozide Must not be co-administered; a 14-day separation period is required after discontinuing an MAOI.
Serotonergic Risk Other serotonergic agents, triptans, St. John's Wort Co-administration may increase the risk of Serotonin Syndrome; requires patient monitoring.
Bleeding Risk NSAIDs, Aspirin, Warfarin, other anticoagulants Combined use may increase the documented risk of bleeding or bruising; close monitoring of prothrombin time is required for co-administration with warfarin.
Exposure Changes Cimetidine, CYP2D6 substrates, Protein-bound drugs Cimetidine increases Serta plasma levels. Serta acts as a mild-to-moderate CYP2D6 inhibitor, requiring potential dosage reduction for co-administered CYP2D6 substrates. Monitoring is required for co-administration with other highly protein-bound drugs, such as phenytoin.

Serta's official interaction profile establishes non-negotiable do-not-combine restrictions, such as with Pimozide. Furthermore, the profile documents required monitoring or cautions, specifically when co-administered with medications that affect blood clotting or those metabolized by CYP2D6 liver enzymes, where a pharmacokinetic change is observed. Use in patients with hepatic impairment also requires specific consideration due to potential for reduced clearance.

Mechanism of Action

Selective Serotonin Reuptake Inhibition

This domain involves the primary mechanism of action: blocking the reuptake of the neurotransmitter serotonin (5-HT) via the serotonin transporter (SERT) protein. This targeted action increases the concentration and availability of 5-HT in the synaptic cleft, resulting in increased serotonergic activity within the central nervous system.

Downstream Receptor Modulation

Chronic engagement of the primary mechanism initiates a cascade of molecular changes within the pathways, including the gradual down-regulation of certain pre-synaptic receptors (such as 5-HT1A autoreceptors) and brain norepinephrine receptors. These prolonged molecular adjustments are associated with the downstream physiological adjustments that follow chronic pathway engagement.

Minor Secondary Binding Effects

Beyond its primary target, the drug displays a notably higher affinity for the sigma-1 (sigma1) receptor, as well as weak inhibition of the dopamine transporter (DAT). These engagements represent mechanisms that influence feedback regulation and contribute to the observed pattern of pathway modulation.

Dosage and Administration Information

How to Use Sertraline (Serta): Administration Guidelines

Sertraline is approved for oral administration and is taken once daily. The medicine is available as tablets (25 mg, 50 mg, 100 mg) and an oral concentrate solution (20 mg/mL). The dosage regimen is highly specific and dictated by the approved indication.

Standard Dosage and Titration

Treatment is typically initiated at a low daily amount. For conditions such as Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD), the adult starting dose is usually 50 mg per day. For Panic Disorder (PD), Posttraumatic Stress Disorder (PTSD), and Social Anxiety Disorder (SAD), the initial dose is 25 mg per day, increasing to 50 mg after the first week. The maximum recommended daily dose for these indications is 200 mg.

Adjustments to the dose are made gradually, in increments of 25 mg or 50 mg, and should occur no more frequently than once per week. This schedule is based on the drug's half-life, allowing steady-state plasma concentrations to be reached.

Administration Requirements

Administration Aspect Instruction
Tablet Intake May be administered with or without food.
Oral Concentrate Must be diluted immediately before use with 4 ounces (1/2 cup) of water, ginger ale, lemon-lime soda, lemonade, or orange juice.
Hepatic Adjustment The starting and maximum daily doses must be reduced by half in patients with mild hepatic impairment.
Missed Dose If a dose is missed, patients should skip the missed dose and take the next dose at the regularly scheduled time; the dose should not be doubled.

Pediatric use is generally limited to Obsessive-Compulsive Disorder. For children aged 6 to 12, the initial dose is lower at 25 mg daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sertraline

Evidence for Use in Major Depressive Disorder (MDD) and Anxiety

Sertraline was studied in research exploring symptom patterns related to Major Depressive Disorder (MDD), Panic Disorder (PD), and Social Anxiety Disorder (SAD) through short-term Randomized Controlled Trials (RCTs), as well as systematic reviews of collected data. The collected research examined outcomes related to systemic or functional imbalance, such as changes in overall depressive symptoms using scales like the PHQ-9, alongside measurements of anxiety symptoms and patient-reported outcomes describing perceived discomfort. The research included adults across primary care and specialized mental health settings.

Findings describe patterns observed in the studies, where research monitored how outcomes reflecting daily functioning or activity level and outcomes related to physiological strain or stress were measured; these changes may appear sooner than those measured for core depressive symptoms. The evidence base for acute adult MDD is categorized as High based on the consistency and weight of the study designs. Initial trials sometimes reported mixed results on overall depression scores, and some core depressive symptoms may take longer to show measured changes. This research provides context, but findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Evidence for Use in Obsessive-Compulsive Disorder (OCD) and Posttraumatic Stress Disorder (PTSD)

Research for Obsessive-Compulsive Disorder (OCD) includes both short-term acute trials and long-term studies evaluating sustained outcomes that monitored outcomes related to symptom intensity using specialized clinical scales. This research was evaluated in a broad population that included children, adolescents, and adults. Given the study design, the evidence base is categorized as High for OCD. For Posttraumatic Stress Disorder (PTSD), studies explored outcomes related to posttraumatic symptoms. The evidence base is classified as Moderate because findings were mixed across different populations studied, such as certain veteran groups.

What is Still Uncertain in the Research Record

Key limitations exist across the evidence base. For many conditions, long-term effects are not fully established, and follow-up durations were limited in many of the initial pivotal trials. The results apply only to the populations studied and do not provide individual predictions. Research is ongoing to better understand why some study participants experience an initial measured change in anxiety symptoms, while core depressive symptoms may take longer to register a measured change.

Key Studies & References Depression in adults: treatment and management (NICE Guideline NG222)

How should Serta be stored and disposed of?

Storage Requirements

Sertraline tablets and oral solutions must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The medication should be kept in its original container with the lid tightly closed to protect it from moisture and heat. The oral concentrate solution must not be frozen.

Child-Safety Storage

As required by regulatory labeling, all forms of sertraline must be stored out of the reach of children.

Official Disposal Instructions

Unused or expired sertraline should primarily be discarded through a community drug take-back program. If no take-back option is available, the medicine must be mixed with an undesirable substance (such as used coffee grounds or cat litter) in a sealed bag or container before being placed in the household trash. Sertraline is not on the official list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Serta found in:

A-Z Index: